AtriCure Board of Directors member Sven Wehrwein sold 10,000 shares valued at $377,000, representing a significant portion of his holdings. Despite the sale, the company shows potential with 16% year-over-year sales growth and improving financial metrics.

Questex's Fierce Healthcare announces the finalists of the second annual Fierce DEI Awards, which celebrate outstanding achievements in Diversity, Equity, and Inclusion within the healthcare industry. The finalists include organizations, initiatives, and individuals recognized for their contributions to creating a more equitable and inclusive healthcare environment.

AtriCure, a medical device company, has received approval from China's National Medical Products Administration to market its AtriClip Left Atrial Appendage Exclusion System in China. This is a key development in the company's global expansion strategy, as China represents a significant market opportunity.

In the latest quarter, 6 analysts provided ratings for AtriCure (NASDAQ:ATRC), showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 1 0 0 0 Last 30D 1 0 0 0 0 1M Ago 1 1 0 0 0 2M Ago 0 0 0 0 0 3M Ago 3 0 0 0 0 Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $44.0, along with a high estimate of $58.00 and a low estimate of $32.00. A 10.66% drop is evident in the current average compared to the previous average price target of $49.25. Deciphering Analyst Ratings: An In-Depth Analysis A comprehensive examination of how financial experts perceive AtriCure is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Mike Matson Needham Lowers Buy $40.00 $46.00 Suraj Kalia Oppenheimer Announces Outperform $32.00 - Mike Matson Needham Maintains Buy $46.00 - Danielle Antalffy UBS Raises Buy $58.00 $57.00 Rick Wise Stifel Lowers Buy $42.00 $50.00 Mike Matson Needham Raises Buy $46.00 $44.00 Key Insights: Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to AtriCure. This information offers a snapshot of how analysts perceive the ...Full story available on Benzinga.com

The headline numbers for AtriCure (ATRC) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

AtriCure (ATRC) delivered earnings and revenue surprises of -19.05% and 2.19%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

AtriCure (ATRC) unveils its cryoSPHERE+ cryoablation probe, which is intended to reduce freeze times and aid in postoperative pain management.

In the preceding three months, 4 analysts have released ratings for AtriCure (NASDAQ:ATRC), presenting a wide array of perspectives from bullish to bearish. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 0 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 3 0 0 0 0 3M Ago 0 0 0 0 0 In the assessment of 12-month price targets, analysts unveil insights for AtriCure, presenting an average target of $48.0, a high estimate of $58.00, and a low estimate of $42.00. This current average represents a 4.63% decrease from the previous average price target of $50.33. Analyzing Analyst Ratings: A Detailed Breakdown An in-depth analysis of recent analyst actions unveils how financial experts perceive AtriCure. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Mike Matson Needham Maintains Buy $46.00 - Danielle Antalffy UBS Raises Buy $58.00 $57.00 Rick Wise Stifel Lowers Buy $42.00 $50.00 Mike Matson Needham Raises Buy $46.00 $44.00 Key Insights: Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to AtriCure. This offers insight into analysts' perspectives on the current state of the company. Rating: Analysts unravel qualitative evaluations for ...Full story available on Benzinga.com

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Piper Sandler raised the price target for Toast, Inc. (NYSE: TOST) from $18 to $20. Piper Sandler analyst Clarke Jeffries maintained a Neutral rating. Toast shares fell 4.7% to close at $19.20 on Thursday. See how other analysts view this stock. Canaccord Genuity boosted Coinbase Global, Inc. (NASDAQ: COIN) price target from $140 to $240. Canaccord Genuity analyst Joseph Vafi maintained a Buy rating. Coinbase shares gained 3.3% to close at $165.67 on Thursday. See how other analysts view this stock. Needham boosted the price target for AtriCure, Inc. (NASDAQ: ATRC) from $44 to $46. Needham analyst Mike Matson maintained a Buy rating. AtriCure shares rose 5.1% to close at $34.21 on ...

In the last three months, 4 analysts have published ratings on AtriCure (NASDAQ:ATRC), offering a diverse range of perspectives from bullish to bearish. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 1 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 1 0 0 0 0 3M Ago 1 1 0 0 0 Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $49.75, a high estimate of $60.00, and a low estimate of $44.00. Witnessing a positive shift, the current average has risen by 6.99% from the previous average price target of $46.50. Analyzing Analyst Ratings: A Detailed Breakdown The analysis of recent analyst actions sheds light on the perception of AtriCure by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Mike Matson Needham Raises Buy $46.00 $44.00 Mike Matson Needham Lowers Buy $44.00 $49.00 Daniel Stauder JMP Securities Maintains Market Outperform $60.00 - Mike Matson Needham Maintains Buy $49.00 - Key Insights: Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent ...Full story available on Benzinga.com

The headline numbers for AtriCure (ATRC) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

AtriCure (ATRC) delivered earnings and revenue surprises of 4.55% and 0.04%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?